Cytokinetics, Inc. : Cytokinetics, Incorporated Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market

  Cytokinetics, Inc. : Cytokinetics, Incorporated Announces Listing Transfer
              from NASDAQ Global Market to NASDAQ Capital Market

South San Francisco, CA - December 18, 2012 - Cytokinetics, Incorporated
(NASDAQ: CYTK), announced today that NASDAQ has approved the Company's request
to voluntarily transfer the listing of its shares of common stock from The
NASDAQ Global Market to The NASDAQ Capital Market. The transfer will be
effective at the opening of business on December 20, 2012 and the Company's
common stock will continue to trade under the symbol "CYTK".

As previously reported, on June 18, 2012, NASDAQ notified the Company that its
listed  security  no  longer  met  the  minimum  $1.00  bid  price  per  share 
requirement, and  subsequently the  Company was  unable to  regain  compliance 
within the 180 calendar day period provided. NASDAQ has determined,  however, 
that upon transfer to The NASDAQ  Capital Market, the Company is eligible  for 
an additional 180 calendar  day period, or  until June 17,  2013, to meet  the 
minimum $1.00 bid  price per share  requirement. If at  any time during  this 
additional time period the closing bid  price of the Company's security is  at 
least $1.00  per share  for a  minimum of  10 consecutive  business days,  the 
Company will be  in compliance  with the requirement  and the  matter will  be 
closed.

The NASDAQ Capital Market is one of the three markets for NASDAQ-listed  stock 
and operates in the same manner as The NASDAQ Global Market. Companies listed
on The  NASDAQ Capital  Market must  meet certain  financial requirements  and 
adhere to NASDAQ's corporate governance standards.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide  (excluding Japan)  to develop  and commercialize  omecamtiv 
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization  participation  rights.  Cytokinetics  is  independently 
developing tirasemtiv, a skeletal muscle  activator, as a potential  treatment 
for  diseases  and  conditions  associated  with  aging,  muscle  wasting   or 
neuromuscular dysfunction. Tirasemtiv is currently  the subject of a Phase  II 
clinical trials program and has been granted orphan drug designation and  fast 
track status by  the U.S. Food  and Drug Administration  and orphan  medicinal 
product designation  by  the  European  Medicines  Agency  for  the  potential 
treatment  of  amyotrophic  lateral  sclerosis,  a  debilitating  disease   of 
neuromuscular  impairment  in   which  treatment   with  tirasemtiv   produced 
potentially clinically relevant  pharmacodynamic effects in  Phase II  trials. 
All of these  drug candidates  have arisen from  Cytokinetics' muscle  biology 
focused research activities  and are  directed towards  the cytoskeleton.  The 
cytoskeleton is a complex biological  infrastructure that plays a  fundamental 
role within every human cell. Additional information about Cytokinetics can be
obtained at www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to the properties and potential benefits of  Cytokinetics' 
drug candidates and potential  drug candidates. Such  statements are based  on 
management's current expectations,  but actual results  may differ  materially 
due to  various  risks  and  uncertainties, including,  but  not  limited  to, 
potential difficulties  or  delays  in the  development,  testing,  regulatory 
approval and production  of Cytokinetics' drug  candidates and potential  drug 
candidates  that  could  slow  or  prevent  clinical  development  or  product 
approval, including risks that current and past results of clinical trials  or 
preclinical studies may not  be indicative of  future clinical trials  results 
and that Cytokinetics' drug candidates and potential drug candidates may  have 
unexpected adverse  side  effects  or  inadequate  therapeutic  efficacy.  For 
further information regarding these and  other risks related to  Cytokinetics' 
business, investors should consult  Cytokinetics' filings with the  Securities 
and Exchange Commission.

Contact:
Jodi L. Goldstein
Manager, Marketing & Corporate Communications

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1666146
 
Press spacebar to pause and continue. Press esc to stop.